
Acorda Therapeutics ACOR
Quarterly report 2024-Q1
added 05-16-2026
Acorda Therapeutics Interest Expense 2011-2026 | ACOR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.5 M | 30.2 M | 30 M | 30.6 M | 21.9 M | 21.6 M | 18.7 M | 16.5 M | 15.5 M | 9.29 M | 2.17 M | 1.88 M | 3.57 M | 3.92 M | -4.42 M | 5.59 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.5 M | -4.42 M | 14.9 M |
Quarterly Interest Expense Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.44 M | 7.98 M | 7.77 M | 7.57 M | - | 7.46 M | 7.47 M | 7.56 M | - | 7.17 M | 7.7 M | 7.82 M | - | 7.76 M | 7.48 M | 7.57 M | - | 4.5 M | 5.38 M | 6.42 M | - | 5.42 M | 5.41 M | 5.5 M | - | 4.18 M | 5.46 M | 4.14 M | - | 4.4 M | 4.03 M | 3.72 M | - | 4.04 M | 4.01 M | 4.05 M | - | 4.6 M | 426 K | 92 K | - | 544 K | 749 K | 591 K | - | 373 K | 356 K | 766 K | - | 947 K | 1.28 M | 1.14 M | 944 K | 1.19 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.44 M | 92 K | 4.39 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
1.06 M | $ 32.59 | -6.89 % | $ 877 M | ||
|
Forte Biosciences
FBRX
|
-396 K | $ 21.59 | -1.86 % | $ 280 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 92.14 | 1.33 % | $ 22.3 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.7 | 3.03 % | $ 452 M | ||
|
Heron Therapeutics
HRTX
|
1.34 M | $ 0.86 | -1.42 % | $ 143 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.8 | 7.28 % | $ 262 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Incyte Corporation
INCY
|
25.1 M | $ 97.16 | -0.26 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
17.3 M | $ 75.56 | -0.29 % | $ 12.1 B | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.4 | -1.16 % | $ 5.6 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.61 | 2.55 % | $ 189 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M |